[HTML] thelancet.comFull View

[HTML][HTML] A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins, NE Ingraham… - …, 2021 - thelancet.com
Abstract Background The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme
2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung …
被引用次数：64 相关文章
[PDF] academia.edu

[PDF][PDF] A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskaricha, NW Cumminsc, NE Ingrahamd… - 2021 - academia.edu
ABSTRACT Background: The SARS-CoV-2 virus enters cells via Angiotensin-converting
enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing …

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins… - …, 2021 - mayoclinic.elsevierpure.com
Background: The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2
(ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung …
[HTML] sciencedirect.com

[HTML][HTML] A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins, NE Ingraham… - eClinicalMedicine, 2021 - Elsevier
Abstract Background The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme
2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung …
[PDF] google.com

[PDF][PDF] A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins, NE Ingraham… - 2021 - drive.google.com
ABSTRACT Background: The SARS-CoV-2 virus enters cells via Angiotensin-converting
enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing …

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2
(ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung …

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins, NE Ingraham… - …, 2021 - experts.umn.edu
Background: The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2
(ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung …

[引用][C] A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins, NE Ingraham… - …, 2021 - cir.nii.ac.jp
A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with
COVID-19 | CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 …

A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19.

MA Puskarich, NW Cummins, NE Ingraham… - 2021 - cabidigitallibrary.org
Abstract Background: The SARS-CoV-2 virus enters cells via Angiotensin-converting
enzyme 2 (ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing …
[HTML] nih.gov

[HTML][HTML] A multi-center phase II randomized clinical trial of losartan on symptomatic outpatients with COVID-19

MA Puskarich, NW Cummins, NE Ingraham… - …, 2021 - ncbi.nlm.nih.gov
Background The SARS-CoV-2 virus enters cells via Angiotensin-converting enzyme 2
(ACE2), disrupting the renin-angiotensin-aldosterone axis, potentially contributing to lung …